Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 1.00 |
| ▸ | SRC | P12931 | 12/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468190 | 1.00 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL29571986 | 1.00 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL22681324 | 0.91 | FGFR1 (0.84) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL20033384 | 0.91 | FGFR1 (0.84) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL18813993 | 0.91 | FGFR1 (0.84) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL23879897 | 0.88 | FGFR1 (0.79) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL1249524 | 0.88 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL2252904 | 0.88 | FGFR1 (0.78) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL13498143 | 0.87 | FGFR1 (0.83) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL5762318 | 0.86 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| WO-2020242910-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (US) | 2020-12-03 | — | — | WO | claimed |
| EP-2233174-B1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | UNIV EMORY (US) | 2016-07-20 | — | — | EP | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| EP-1744735-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | The Scripps Research Institute (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| JP-2005533604-A | — | — | 2005-11-10 | — | — | JP | claimed |
| WO-2005089366-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | claimed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| US-20040214836-A1 | Method of treatment of myocardial infarction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-28 | — | — | US | claimed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | disclosed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214836-A1 | Method of treatment of myocardial infarction | SRC, LCK, DSTYK | FGFR1 914/4885SRC 1/4885ABL1 5/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | FGFR1 4698/4885SRC 2604/4885ABL1 3158/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | FGFR1 118/4885SRC 9/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.